HNSBF - Hansa Biopharma AB (publ) (HNSBF) Q1 2024 Earnings Call Transcript

2024-04-18 11:45:23 ET

Hansa Biopharma AB (publ). (HCHDF)

Q1 2024 Earnings Conference Call

April 18, 2024, 08:00 AM ET

Company Participants

Søren Tulstrup - Chief Executive Officer

Matt Shaulis - Chief Commercial Officer and U.S. President

Hitto Kaufmann - Chief Scientific Officer

Evan Ballantyne - Chief Financial Officer

Conference Call Participants

Christopher Uhde - SEB

Douglas Tsao - H.C. Wainwright

Alexander Krämer - ABG

Johan Unnerus - Red Eye

Presentation

Operator

Hi, everyone, and welcome to the Hansa Biopharma Interim Report for Q1 2024. Today's call is being recorded. For the first part of this call, all participants will be in a listen-only mode. Afterwards, there'll be a question-and-answer session. [Operator Instructions] Speakers, please begin.

Søren Tulstrup

Thank you operator. Good afternoon, good morning and welcome to the Hansa Biopharma Conference call to review first quarter results for 2024. I'm Søren Tulstrup, CEO of Hansa Biopharma. Joining me today is our Chief Commercial Officer and U.S. President, Matt Shaulis; our Chief Scientific Officer, Hitto Kaufmann. I’m also delighted to welcome Evan Ballantyne as our new Chief Financial Officer. With Evans, deep international experience and successful track record as a CFO at public and private life science companies I am confident that Evan will be a strong addition to our team and will help drive our financial strategy, deliver on key strategic priorities, and help us build shareholder value.

Hansa's head of investor relations, Klaus Sindahl, is also with us. Today, we'll discuss the progress we made during the first quarter of 2024 and review our near-term milestones. Presentations should take roughly 15 to 20 minutes, after which there will be an opportunity to ask questions during a Q&A session.

Now, please turn to slide two. Please allow me to draw your attention to the fact that we will be making forward-looking statements during this presentation, and you should therefore apply appropriate caution. Please turn to slide three and an overview of Q1 highlights. I'm very pleased to see a promising start to 2024. In the first quarter, we continue to see strong commercial execution, making it our best-performing quarter so far, and the second consecutive quarter with solid product sales. This strong sales performance is a continuation of the tracks you saw at the end of last year, where key large markets such as the U.K. and Germany started to contribute, supported by new and repeated use of Idefirix’s leading transplant centers. Matt will cover the commercial performance in more detail during his section of the call.

Last week, we announced that additional financing has been secured, extending our cash runway into 2026 through a $34.6 million direct-to-share issue targeting national healthcare specialist investors. I'm very pleased to see a strong interest in the hands-on equity story from leading U.S. and European specialist investors. This transaction will help finance the preparation for potential U.S. launch of imlifidase in kidney transplantation, strengthen our ongoing product development in autoimmune indications and allow for the continued clinical development of HNSA-5487, our lead candidate from the NiceR program for repeat dosing....

For further details see: